“Someone turned the R&D lights on for big pharma
Post# of 144481
![Avatar](/images/ProfileImages/573000060_60093_FD245EF6-37BD-4C88-9356-29519D0376AD.jpeg)
Based on the PR, these suitors have already chosen their COVID cocktail and leronlimab is not part of that cocktail. I mentioned this recently: NP once said he turned down an offer to combine leronlimab in a trial with another treatment. I always thought he was referring to remdesevir but maybe it was for a different cocktail.
I can’t understand how BP wouldn’t identify leronlimab as a potential cocktail ingredient given the MOA, HIV results. eIND results, M2M results Nd safety profile. Just doesn’t make much scientific sense.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)